Presentations & Publications

We are proud of our scientific progress, much of which has been documented via various presentations and publications.

Since 2011, our proprietary platform has enabled the design of three new clinical drug candidates, resulting in four clinical programs. Our scientific progress has been documented in various national and international presentations and publications.

July 2020

Phase I/II, Open-Label, Ongoing Study of Rilzabrutinib (PRN1008), an Oral Bruton Tyrosine Kinase Inhibitor, in Patients With Heavily Pretreated Immune Thrombocytopenia

June 2020

BELIEVE-PV Phase II Part B Study: Extended Treatment With PRN1008 (Rilzabrutinib) For Patients With Pemphigus

June 2020

Safety and Efficacy of Rilzabrutinib (PRN1008), an Oral Bruton Tyrosine Kinase Inhibitor, in Relapsed/Refractory Patients With Primary or Secondary Immune Thrombocytopenia: Phase I/II Adaptive Study

December 2019

Phase I/II, Open-Label, Adaptive Study of Oral Bruton Tyrosine Kinase Inhibitor PRN1008 in Patients With Relapsed/Refractory Primary or Secondary Immune Thrombocytopenia

October 2019

A Randomized, Double-Blind, Placebo and Active Controlled, Global Multicenter Trial to Evaluate the Efficacy and Safety of Oral BTK Inhibitor PRN1008 in Moderate to Severe Pemphigus

September 2019

Preclinical Mechanisms of Action of PRN1008, a Reversible Covalent Bruton’s Tyrosine Kinase Inhibitor in Clinical Development for Pemphigus

May 2019

A phase 1, multicenter, dose-escalation study of PRN1371, an irreversible covalent FGFR1-4 kinase inhibitor, in patients with advanced solid tumors including metastatic urothelial carcinoma (mUC)

February 2019

Phase 1 Clinical Trial of PRN2246 (SAR442168), a Covalent BTK Inhibitor Demonstrates Safety, CNS Exposure and Therapeutic Levels of BTK Occupancy

Advancing Promising Therapies

Principia is now a Sanofi company.

As of September 28, 2020, Sanofi and Principia have joined forces to expand and accelerate the potential benefits of therapies for patients with immune-mediated diseases. We will work together to bring these novel therapies to patients faster. Read press release.

Enter Website